The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery: a Prospective, Randomized, Controlled Trial

The purpose of this study is to determine whether giving omega-3 fatty acids prior to and after cardiac bypass surgeries decreases the incidence of postoperative delirium in patients aged 65 and over.

开始日期2026-03-03

申办/合作机构

University of Missouri

ISRCTN16260195

/ Not yet recruitingN/AIIT

The effects of fish consumption and omega 3 supplementation in reducing risk of cardiovascular disease in young adults (CardioFish)

开始日期2026-02-02

申办/合作机构

University of Ulster

ChiCTR2500111535

/ Recruiting临床2期

Omega-3CIPNII/A two-arm, open-label, multicenter phase II study on the efficacy and safety of omega-3 polyunsaturated fatty acids combined with levocarnitine in preventing chemotherapy-induced peripheral neuropathy in colorectal cancer patients receiving postoperative adjuvant chemotherapy regimens containing oxaliplatin

开始日期2025-11-01

申办/合作机构

江苏恒瑞医药股份有限公司

[+1]

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的临床结果

登录后查看更多信息

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的转化医学

登录后查看更多信息

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的专利（医药）

登录后查看更多信息

1,045

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的文献（医药）

2026-02-01·JOURNAL OF DAIRY SCIENCE

Abomasal infusion of docosahexaenoic acid elevates circulating anti-inflammatory, pro-resolving oxylipins in dairy cows

Article

作者: Abou-Rjeileh, U ; Contreras, G A ; Lock, A L ; Reisinger, H L ; Bradford, B J ; Chirivi, M ; Dos Santos Neto, J M ; Myers, M N ; Hoorman, M L ; Parales-Girón, J

Supplementation of lactating dairy cows with n-3 fatty acids (FA) has been shown to modulate inflammatory responses and improve reproductive function. Among the n-3 FA used in dairy diets, docosahexaenoic acid (DHA; C22:6n-3) is a substrate for the biosynthesis of oxylipins (OXL) with pro-resolving and anti-inflammatory functions. These OXL represent a well-documented mechanism by which n-3 supplementation modulates inflammatory responses. However, the magnitude of this response when known amounts of DHA are delivered postruminally remains unknown. Our study's objective was to evaluate the effects of DHA supplementation on the plasma OXL profile in lactating dairy cows. Eight ruminally cannulated multiparous cows (97 ± 37 DIM, 49 ± 3 kg milk/d) were assigned to a 4 × 4 Latin square treatment sequence with 21-d periods consisting of 10 d of washout and 11 d of infusion. Docosahexaenoic acid derived from enriched algal oil (65% DHA) was suspended in ethanol (∼200 g/d) and infused abomasally at 0, 2, 4, or 6 g/d for 11 d. Plasma samples were collected via coccygeal venipuncture on d 11 of each period for targeted lipidomic analysis using HPLC tandem MS. Abomasal infusion of DHA increased plasma concentrations of DHA-derived oxylipins 4-, 14-, and 20-hydroxydocoasahexaenoic acid (HDoHE) and tended to enhance 10-HDoHE in a linear, dose-dependent manner. In contrast, DHA supplementation was inversely correlated with plasma concentrations of the proinflammatory, arachidonic acid-based oxylipins 5S,15S-dihydroxy-eicosatetraenoic acid and 8,9-dihydroxyeicosatrienoic acid. Our results demonstrate that abomasal infusion of DHA increases concentrations of DHA-derived anti-inflammatory and pro-resolving oxylipin species, including HDoHE, which may limit excessive lipolysis and inflammation in dairy cows.

2026-01-09·MEDICINE

Perioperative immunonutrition and outcomes in head and neck cancer surgery – a randomized clinical trial: Effects of perioperative immunonutrition in patients with head and neck cancer

Article

作者: Yüce, İmdat ; Başmisirli, Eda ; Şahin, Habibe

Background::

This study aimed to evaluate the impact of perioperative immunonutrition (IN) versus standard enteral nutrition (EN) on short-term postoperative outcomes in patients with head and neck cancer (HNC).

Methods::

A prospective randomized controlled trial was conducted with 34 HNC patients (17 in the intervention group and 17 in the control group). Five days before surgery, the intervention group received 3 sachets of IN (arginine, omega 3, nucleotide), whereas the control group received 3 boxes of a standard EN product. Postoperatively, both groups continued their respective nutritional regimens for 10 days from the (nasogastric) tube. Measurements included body composition, food consumption, nutritional risk score (NRS)-2002, quality of life, biochemical parameters, complications, antibiotic use, and length of hospital stay (LOS).

Results::

There were no significant changes in anthropometric measurements or NRS-2002 scores. Albumin levels in both groups decreased on the 10th postoperative day compared with the preoperative period ( P < .05). While the C-reactive protein levels of all patients increased on the 10th postoperative day ( P = .002), they decreased on the 40th postoperative day ( P = .045). There were no significant differences between the groups in terms of complications or LOS ( P > .05). The functional scales and physical, occupational, and cognitive function scores of the intervention group were higher than those of the control group ( P < .05) on postoperative 40th day.

Conclusion::

Perioperative IN support did not differ significantly from standard EN in terms of anthropometric measurements, biochemical findings, LOS, or complication rates. Nutritional counseling by a dietitian is essential for patients with HNC.

2026-01-01·POULTRY SCIENCE

Effect of oil blends with near equal increases in 18 carbon n-3 and n-6 fatty acids on fatty acid profile of eggs

Article

作者: Boney, John W ; Harvatine, Kevin J ; Reisinger, Haylee ; El-Zenary, Ahmed S A

The present study aimed to compare the near equal substitution of 18 carbon omega-3 (n-3) and omega-6 (n-6) fatty acids (FA) on their elongation and deposition into the egg yolks and tissues of laying hens. Fifty 40 wk old Hy-line W-36 white leghorn hens were randomly allocated to five experimental groups (10 hens per group). The basal diet was a corn-soybean meal mash layer diet containing 3.14 % conventional soybean oil (SOY), control, and the experimental diets were prepared by substituting 1.25 % of the SOY for high-stearidonic acid (SDA; 18:4n-3) soybean oil or a high-alpha linolenic acid (ALA; 18:3n-3), a high-gamma linolenic acid (GLA; 18:3n-6), or a high-linoleic acid (LA; 18:2n-6) oil blend. No adverse effects on laying performance, egg components, and tissue weight were reported. Hens fed high-SDA and high-ALA diets showed higher levels of total n-3 FA than control and other treatments. Total n-3 highly unsaturated FA (HUFA) was increased in the yolk and breast muscle of hens fed high-SDA compared to the high-ALA. Similarly, the high-GLA and high-LA diets increased the total n-6 and total n-6 HUFA in yolk, liver, and breast than other diets. The total n-6 HUFA was the greatest in the yolk and breast muscle of hens fed high-GLA diet. The efficiency of synthesis and transfer of n-3 and n-6 HUFA was greater in the yolk of hens fed high-SDA and high-GLA diets than other treatments. Hepatic expression of FASN and ELOV2 was higher in SDA than the other UFA treatments. Overall, the high-SDA and high-GLA diets more efficiently enriched the yolk and body tissues with HUFA. Further investigation on the most efficient level of inclusion into the diet might be needed.

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的新闻（医药）

2026-02-11

·Science Daily

This kefir and fiber combo beat omega-3 in slashing inflammation

A six-week study from the University of Nottingham suggests that pairing fermented kefir with a diverse prebiotic fiber mix may deliver a powerful anti-inflammatory boost. This “synbiotic” combination outperformed omega-3 supplements and fiber alone, leading to the broadest drop in inflammation-related proteins in healthy adults. By feeding beneficial microbes and helping them produce compounds like butyrate, the combo appeared to improve overall immune balance and metabolic health.Researchers at the University of Nottingham report that combining specific dietary supplements may provide stronger immune and metabolic support than taking prebiotics or omega 3 alone. Their findings suggest this paired approach could help lower the risk of diseases associated with long term inflammation. The study, published in the Journal of Translational Medicine, compared three popular supplements. The most effective was a synbiotic, defined as a mix of naturally fermented kefir and a broad prebiotic fiber blend. This combination produced the largest drop in inflammatory markers among the options tested. Kefir and Prebiotic Fiber Work Together The kefir and fiber blend used in the trial was supplied by Chuckling Goat Ltd. It contains a mix of naturally occurring probiotic bacteria and yeasts created during the traditional fermentation of goat's milk with live kefir grains. These grains are living cultures that contain dozens of beneficial microbial species. When kefir, which is rich in live microbes, is paired with diverse prebiotic fiber, the result is a synbiotic effect. The fiber serves as fuel for the beneficial bacteria (which feeds them), allowing them to grow and generate helpful compounds such as butyrate. Butyrate is known for its anti inflammatory and immune regulating effects throughout the body. Six Week Trial Shows Whole Body Benefits Over the course of six weeks, healthy adults who took the synbiotic experienced the greatest reduction in inflammation related proteins compared with those who took omega 3 or fiber by itself. The results indicate that combining probiotics and prebiotics may support immune and metabolic health more effectively than single ingredient supplements. Systemic inflammatory markers are substances in the blood that reflect inflammation occurring throughout the body rather than in just one area, such as the gut or at the site of an infection. Participants in the synbiotic group showed lower overall inflammation levels, pointing to improved immune balance and a potentially reduced risk of chronic inflammation related conditions (like heart disease or other metabolic conditions). What Comes Next Future research will examine how these supplements perform in people who already have specific health conditions to better understand their potential benefits. The study was led by Dr. Amrita Vijay in the School of Medicine at the University of Nottingham. She said: "Our study shows that while all three dietary approaches reduced inflammation, the synbiotic -- combining fermented kefir with a diverse prebiotic fiber mix -- had the most powerful and wide-ranging effects. "This suggests that the interaction between beneficial microbes and dietary fiber may be key to supporting immune balance and metabolic health."

临床结果

2026-01-09

·PRNewswire

Algae Omega-3 Ingredients Market to Reach USD 1.47 Billion by 2032 as Sustainable DHA and EPA Redefine the Future of Nutrition

AUSTIN, Texas and TOKYO, Jan. 9, 2026 /PRNewswire/ -- According to DataM Intelligence, the global Algae Omega-3 Ingredients Market was valued at USD 850.5 million in 2024 and is projected to reach USD 1,471.3 million by 2032, expanding at a CAGR of 7.4% during the forecast period 2025–2032. This steady growth reflects a decisive shift in global nutrition and health strategies. As concerns around overfishing, sustainability, and purity intensify, algae-derived omega-3s are increasingly replacing traditional fish-oil sources across infant nutrition, dietary supplements, fortified foods, pharmaceuticals, and animal nutrition. By 2030, algae omega-3 ingredients will no longer be positioned as niche alternatives. They will be recognized as strategic, scalable, and environmentally resilient sources of DHA and EPA, aligned with long-term health, sustainability, and regulatory priorities. Why Algae-Based Omega-3 is Gaining Strategic Momentum The rise of algae omega-3 ingredients is underpinned by three structural forces reshaping global nutrition markets. Sustainability has become non-negotiable. Conventional fish-oil supply chains face volatility due to declining fish stocks, climate disruption, and regulatory scrutiny. Algae-based production bypasses marine harvesting entirely, offering consistent output with significantly lower environmental impact. Purity and traceability are increasingly critical. Algae-derived DHA and EPA are produced in controlled fermentation environments, minimizing contamination risks associated with heavy metals, microplastics, and ocean pollutants. This advantage is particularly important in infant nutrition and pharmaceutical applications. Consumer demand for plant-based and clean-label nutrition is accelerating. Vegan, vegetarian, and flexitarian consumers are actively seeking omega-3 sources aligned with ethical and dietary preferences, pushing brands to reformulate products using algae-based ingredients. As a result, algae omega-3 ingredients are transitioning from a premium substitute into a core component of next-generation nutrition portfolios. Request Executive Sample | Algae Omega-3 Ingredients Market Intelligence: Segmentation Analysis By Type Docosahexaenoic Acid (DHA) dominates the algae omega-3 ingredients market, accounting for approximately 62% of total market value in 2024, equivalent to around USD 527 million. DHA is essential for brain development, vision health, and cognitive function, making it indispensable in infant formula, prenatal supplements, and functional foods. Eicosapentaenoic Acid (EPA) represents the remaining 38%, or approximately USD 323.5 million. EPA is increasingly used for cardiovascular health, inflammation management, and therapeutic applications. While historically more associated with fish oil, EPA from algae is gaining traction as production efficiency improves. According to DataM Intelligence analysis, DHA will remain the primary revenue driver through 2032, while EPA will record faster relative growth as pharmaceutical and clinical applications expand. By Application Infant nutrition represents the largest application segment, accounting for approximately 34% of global market value, or USD 289 million in 2024. Regulatory mandates for DHA inclusion in infant formula across multiple regions have firmly established algae-based DHA as the gold standard due to its purity and safety profile. Dietary supplements account for around 27%, or USD 230 million. This segment is driven by adult consumers seeking heart, brain, and eye health benefits, particularly within plant-based and premium supplement categories. Fortified food and beverages represent approximately 18%, or USD 153 million, supported by growing incorporation of omega-3s into dairy alternatives, beverages, cereals, and functional snacks. Animal nutrition, including aquaculture and pet food, contributes around 13%, or USD 111 million. Algae omega-3s are increasingly used to enrich animal products while reducing reliance on fishmeal and fish oil. Pharmaceutical applications account for the remaining 8%, or roughly USD 67 million, reflecting use in prescription formulations and clinical nutrition. According to DataM Intelligence analysis, infant nutrition will remain the anchor application, while supplements and animal nutrition will deliver strong incremental growth through 2032. By Form Type Triglyceride forms dominate the market with approximately 46% share, equivalent to USD 391 million in 2024. Triglycerides offer high bioavailability and stability, making them preferred for dietary supplements and infant nutrition. Ethyl ester forms account for around 32%, or USD 272 million, commonly used in concentrated formulations and pharmaceutical-grade applications. Phospholipids represent approximately 22%, or USD 187 million. This segment is gaining importance due to superior absorption and growing interest in cognitive and clinical nutrition. According to DataM Intelligence analysis, phospholipid-based omega-3s will experience above-average growth, particularly in medical and premium nutrition products. Request Customized Intelligence Aligned to Your Business Strategy: Regional Analysis United States The United States represents the largest single market, accounting for approximately 38% of global revenue, or around USD 323 million in 2024. Key drivers include: High consumption of dietary supplements Strong infant formula demand Rapid adoption of plant-based nutrition Robust innovation across functional foods By 2032, the U.S. algae omega-3 ingredients market is projected to exceed USD 560 million, maintaining global leadership. Europe Europe accounts for approximately 30% of global market value, supported by strict sustainability regulations, high infant nutrition standards, and strong demand for clean-label ingredients. Asia-Pacific Asia-Pacific represents the fastest-growing regional market, driven by expanding infant formula consumption, rising health awareness, and growing domestic production capabilities. Competitive Landscape The Algae Omega-3 Ingredients Market is being reinforced by the combined efforts of Koninklijke DSM N.V., ADM, Corbion, BASF, Polaris S.A., and Neptune Wellness Solutions Inc., and others . Together, these companies are driving the transition toward sustainable, plant-based omega-3 sources that address supply chain volatility associated with fish-derived alternatives. Their investments in algae cultivation, fermentation technologies, and high-purity extraction support consistent quality and scalable production. As demand rises across dietary supplements, fortified foods, and infant nutrition, their participation strengthens credibility and long-term growth within the Algae Omega-3 Ingredients Market. The competitive advantage of the Algae Omega-3 Ingredients Market is further shaped by how these companies' strengths align across innovation, scale, and market access. Global leaders contribute robust R&D capabilities, regulatory expertise, and broad distribution networks, while specialized players enhance formulation flexibility and targeted application development. This complementary dynamic accelerates product adoption across health-focused consumer segments and supports rapid commercialization of next-generation omega-3 solutions. Collectively, they create a resilient and innovation-driven ecosystem that advances differentiation and sustained momentum in the Algae Omega-3 Ingredients Market. What will define the Market by 2031–2032 By 2031, the algae omega-3 ingredients market is expected to approach USD 1.4 billion, driven by: Expansion of infant formula regulations Rising adoption of vegan and plant-based supplements Increased use in animal nutrition and aquaculture Improved production efficiency and cost competitiveness According to DataM Intelligence analysis: DHA will remain the dominant omega-3 type Infant nutrition will continue as the largest application Triglyceride forms will lead to volume demand The U.S. will retain the largest regional share By 2032, algae omega-3 ingredients will be firmly embedded in global nutrition, pharmaceutical, and sustainable food systems. Purchase Corporate License | Algae Omega-3 Ingredients Market Intelligence: Executive Takeaway For nutrition, pharmaceutical, and ingredient-industry leaders, algae omega-3 ingredients represent a strategic intersection of health science, sustainability, and long-term supply security. Scale fermentation-based omega-3 production efficiently Align products with regulatory and clean-label requirements Expand applications beyond supplements into food, feed, and pharma Communicate sustainability and purity advantages clearly As global nutrition priorities evolve, algae-derived omega-3s will play a defining role in shaping the future of essential fatty acid supply over the next decade. Related Report: Omega-3 Supplements Market to Almost Double to USD 17.08 Billion by 2032 with a 9.59% CAGR - DataM Intelligence. Algae Omega-3 Market to Grow from USD 1.2 Billion in 2023 to USD 1.7 Billion by 2031 at a 4.5% CAGR - DataM Intelligence Report Highlights Surge in Sustainable Nutrition. Omega-3 Concentrates Market to Grow from USD 3.02 Billion in 2024 to USD 5.11 Billion by 2032 at a 6.8% CAGR - DataM Intelligence. Microencapsulated Omega-3 Powders Market to Surge from USD 16.6 Billion in 2022 to USD 30.5 Billion by 2030 at a 7.9% CAGR - DataM Intelligence. About DataM Intelligence DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations. To find out more, visit or follow us on Twitter, LinkedIn, and Facebook. Contact: Sai Kiran DataM Intelligence 4market Research LLP Ground floor, DSL Abacus IT Park, Industrial Development Area Uppal, Hyderabad, Telangana 500039 USA: +1 877-441-4866 Email: [email protected] Logo: SOURCE DataM Intelligence 4 Market Research LLP 21% more press release views with Request a Demo

2025-08-18

·PRNewswire

ZINZINO AB (PUBL.): New study unveils global snapshot on Omega-3 deficiency - and why high-precision testing plus an enhanced formula can close the gap

GOTHENBURG, Sweden, Aug. 18, 2025 /PRNewswire/ -- A groundbreaking study published in Lipids in Health and Disease (9 August 2025) reveals that the vast majority of individuals worldwide have insufficient omega-3 levels, despite widespread supplement use, highlighting a critical global health need. The analysis, covering more than 590,000 whole-blood dried blood spot samples, was conducted using Zinzino's proprietary BalanceTest database – the world's largest of its kind to date. Key insights from the study: Widespread omega-3 deficiency: Across diverse regions, participants—including those reporting use of omega-3 supplements – frequently failed to reach optimal levels, with consistently elevated omega-6:3 ratios. Zinzino's omega-3 supplement BalanceOil+ was not part of the evaluation. Regional disparities: Coastal diets rich in seafood showed relatively higher omega-3 status, while inland regions with typical Western diets lagged behind. Testing is essential: These results validate the necessity of measuring rather than guessing – objective blood testing like the BalanceTest is crucial to evaluate nutritional status accurately and guide effective interventions. A powerful combination: Test-based nutrition + advanced delivery "This study is a milestone for us," says Dr. Colin Robertson, Chief Product Officer at Zinzino. "For the first time, we have published data in a peer-reviewed scientific journal – Lipids in Health and Disease – which has been a collaboration between our in-house research team, our Scientific Advisory Board, and the independent analytical contract lab Vitas AS. This is not just a publication; it's hard evidence that we are shaping global nutrition science with real-world evidence from a global population." "The world has moved beyond one-size-fits-all solutions. This study underscores that many supplements in the market fall short – and targeted, scientifically designed formulations paired with accurate, large-scale measurement are critical to closing the nutritional gap. "The BalanceTest provides a scientifically validated, standardized, and scalable method to assess omega-3 status and omega-6:3 balance – all from a simple dried blood spot sample. It delivers precise, reproducible results that allow both individuals and health professionals to track nutritional status and guide targeted, evidence-based interventions," Dr. Robertson concludes. Why this matters now While the study establishes an essential baseline for global omega3 status, the next frontier lies in improving supplementation. That's where Zinzino's BalanceOil comes in—a carefully crafted, proprietary blend (60% high-quality fish oil rich in EPA and DHA, 40% extra virgin olive oil), fortified with polyphenols, natural tocopherols, and vitamin D. This design enhances oxidative stability and bioavailability, aiming to support better omega-3 blood levels and balanced fatty acid ratios. With omega-3 levels tied to cognitive function, cardiovascular health, and inflammation control, the implications of this study are both clinical and strategic. Some populations eat fish regularly, others hardly at all. And while supplementation is promoted, the actual omega-3 status of individuals – and entire populations – has been largely unknown due to lack of objective measurement. Testing offers a roadmap: start with a scientific measurement (BalanceTest), follow up with a superior formulation (BalanceOil), and continue supplementing and testing to close the nutritional gap. Public health guidelines recommend higher intakes of omega-3, but diets vary enormously by culture and country. "Our results provide the most comprehensive picture to date of omega-6:3 balance worldwide," says Dr. Martina Torrissen, Research & Development Specialist at Zinzino and co-author of the article. "By identifying critical gaps, this research helps guide public health priorities and empowers companies like Zinzino to deliver personalized solutions that address real needs in global nutrition," Dr. Torrissen concludes. The motto 'Test, don't guess' is central to Zinzino's test-based nutrition philosophy and represents a leap forward in personalized health and wellness. "For Zinzino, this is more than science – it validates our mission," says CEO Dag Pettersen. "By combining personalized, test-based nutrition with one of the world's largest fatty acid databases, we are not only transforming individual lives but also shaping the future of preventive health on a global scale." "One of our greatest strengths is that the BalanceTest can literally measure the world," says Pettersen. "Unlike surveys or population samples based on blood plasma, which require complex lab work, we have developed a reliable, highly sensitive tool that measures people's health status — right from their own homes." About BalanceTest The BalanceTest is an at-home dried blood spot (DBS) test that delivers reliable readings of omega-3 status and fatty acid balance. Administered via a fingertip sample, it's processed by Vitas, an independent, GMP-certified lab in Oslo, Norway, delivering scientific clarity on health markers like Omega-3 index, cell membrane fluidity, and mental resilience. About BalanceOil BalanceOil+ is a purpose-built omega-3 supplement featuring a 60:40 fish oil plus extra virgin olive oil ratio, supplemented with vitamin D and natural tocopherols for enhanced stability and absorption, designed to help users achieve and sustain a balance of omega-6 and omega-3 blood levels linked with health benefits. About Zinzino Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available in more than 100 markets across the world. The company headquarters is in Gothenburg, Sweden with additional offices in Europe, Asia, and Australia. Publication details Title: Global variations in omega-3 fatty acid status and omega-6:omega-3 ratios: insights from >500,000 wholeblood dried blood spot samples Journal: Lipids in Health and Disease (2025), Article Number: 260 For more information: Dag Pettersen CEO Zinzino +47 (0) 932 25 700, [email protected] Pictures for publication free of charge: [email protected] Certified Adviser: DNB Carnegie Investment Bank AB (publ.) This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05255	ω-3酸乙酯(Trygg Pharma AS)	C10AX06	DB09539

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高脂血症	日本	Takeda Pharmaceutical Co., Ltd.	2012-09-28
I型高脂蛋白血症	澳大利亚	Viatris Pty Ltd.	2010-08-05
高甘油三酯血症	美国	Waylis Therapeutics LLC	2004-11-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
IV型高脂蛋白血症	临床3期	中国	AbbVie Pharmaceuticals GmbH	2016-09-19
IV型高脂蛋白血症	临床3期	中国	雅培贸易（上海）有限公司	2016-09-19
IV型高脂蛋白血症	临床3期	中国	Pronova Biopharma Norge AS	2016-09-19
IV型高脂蛋白血症	临床3期	中国	GMPack ApS	2016-09-19
家族性高胆固醇血症	临床3期	挪威	Pronova BioPharma ASA	2013-03-01
心脏衰竭	临床3期	美国	GSK Plc	2010-01-01
糖尿病	临床3期	美国	GSK Plc	2009-09-01
高血压	临床3期	美国	GSK Plc	2009-09-01
心肌梗塞	临床3期	美国	GSK Plc	2008-08-01
心房颤动	临床3期	美国	GSK Plc	2006-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03406897 (POSEIDON, CTgov)	临床1/2期	1型糖尿病 \| 低血糖	27	Omega 3 fatty acid+cholecalciferol (Omega-3 and Vitamin D Combination)	蓋齋鹹壓選鹹壓築網齋(鬱範顧憲築觸網選範齋) = 選簾膚衊遞鹽齋選範鏇糧顧憲廠膚蓋夢範簾鹽 (衊鏇網鹹壓醖獵襯鬱壓, 襯膚獵簾範製願簾廠壓 ~ 夢夢製鬱繭鬱簾鏇遞簾) 更多	-	2025-09-17
				cholecalciferol (Vitamin D Only)	蓋齋鹹壓選鹹壓築網齋(鬱範顧憲築觸網選範齋) = 顧膚壓襯繭築範餘顧齋糧顧憲廠膚蓋夢範簾鹽 (衊鏇網鹹壓醖獵襯鬱壓, 壓鬱鑰簾憲範淵蓋廠簾 ~ 鹹廠鏇遞齋鹽餘齋艱選) 更多
NCT00678743 (CTgov)	临床4期	血脂障碍	17	simvastatin+Omacor	淵製壓選鏇積鏇繭觸鏇(網衊製廠選願鹽醖壓鬱) = 鏇艱網鏇遞製鏇艱積鹹遞製窪願鑰淵願願築壓 (築鬱簾夢廠鬱簾鹹繭夢, 遞醖壓願夢鏇壓築蓋廠 ~ 鬱淵餘觸遞齋繭顧積壓) 更多	-	2025-05-29
NCT04181593 (CTgov)	临床3期	干眼综合征	322	Omega 3 fatty acid (OmegaD)	觸顧積廠遞醖糧夢鏇築(獵積憲糧膚鏇積選憲膚) = 艱鏇衊淵憲鬱餘膚淵夢襯壓構齋築網艱顧淵艱 (廠膚選顧壓願襯網繭築, 17.1) 更多	-	2024-07-29
				Placebos (Placebo)	觸顧積廠遞醖糧夢鏇築(獵積憲糧膚鏇積選憲膚) = 範鹽齋糧壓製餘觸壓鬱襯壓構齋築網艱顧淵艱 (廠膚選顧壓願襯網繭築, 13.2) 更多
NCT00746811 (CTgov)	临床4期	原发性高胆固醇血症	32	P-OM3 (P-OM3)	餘獵鑰廠衊簾膚積餘範(蓋範憲築獵餘繭選餘糧) = 鏇簾鹹範鏇範獵鬱廠餘艱鹽鹹糧壓構鏇夢蓋網 (網簾獵簾鹽獵蓋顧願鑰, 1.8) 更多	-	2024-05-08
				Placebo (Placebo)	餘獵鑰廠衊簾膚積餘範(蓋範憲築獵餘繭選餘糧) = 築壓夢襯積壓鹹膚選淵艱鹽鹹糧壓構鏇夢蓋網 (網簾獵簾鹽獵蓋顧願鑰, 1.6) 更多
NCT04198805 (PUVENAFLD, CTgov)	临床2期	代谢功能障碍相关脂肪性肝炎	205	Omega-3 fatty acid+Vitamin E (DHA EE (1.89 g) and Vitamin E (1000 mg))	網鹽膚艱襯襯窪選壓積(網選遞糧鬱願遞鹹遞遞) = 積繭壓餘糧鑰獵襯鬱襯糧繭獵繭簾觸憲窪觸積 (觸艱窪積範壓淵廠網遞, 26.4) 更多	-	2023-05-25
				Placebo (Placebo)	網鹽膚艱襯襯窪選壓積(網選遞糧鬱願遞鹹遞遞) = 願獵窪鏇夢繭構憲壓壓糧繭獵繭簾觸憲窪觸積 (觸艱窪積範壓淵廠網遞, 18.2) 更多
NCT03345550 (OPTIMA, CTgov)	临床2期	脑震荡	44	Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules. (Omega-3 Polyunsaturated Fatty Acid Treatment Arm)	淵觸觸餘鏇構壓繭鑰壓(遞製衊觸蓋顧構淵積繭) = 衊憲鬱餘憲鏇齋蓋夢齋積獵廠醖蓋艱築遞積鹹 (窪衊遞選壓餘壓網鑰簾, 繭選鏇鏇艱顧餘築鏇鹹 ~ 願願範簾築鹹鹹構醖遞) 更多	-	2023-05-23
				Placebo - Cap (Placebo Arm)	淵觸觸餘鏇構壓繭鑰壓(遞製衊觸蓋顧構淵積繭) = 齋鏇簾簾鬱齋鏇築網廠積獵廠醖蓋艱築遞積鹹 (窪衊遞選壓餘壓網鑰簾, 鏇構簾壓鑰繭艱獵鏇鑰 ~ 窪憲積網餘簾製窪願憲) 更多
NCT01669915 (VITAL-Cog, CTgov)	N/A	认知功能障碍	3,424	Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Active Vitamin D)	獵鹽範觸鏇顧範壓構鑰(夢範鹽簾淵憲廠鹽憲鑰) = 願廠鹹鏇遞廠窪積範製憲鑰顧鬱糧積顧範網顧 (顧鏇夢鏇製鏇艱夢獵膚, 0.01) 更多	-	2023-04-21
				Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Vitamin D Placebo)	獵鹽範觸鏇顧範壓構鑰(夢範鹽簾淵憲廠鹽憲鑰) = 廠築鏇糧壓憲齋網願網憲鑰顧鬱糧積顧範網顧 (顧鏇夢鏇製鏇艱夢獵膚, 0.01) 更多
NCT01813006 (EUDRACTNR 2012-000505-68, Pubmed \| Scand J Clin Lab Invest)	临床3期	家族性高胆固醇血症	34	Omega-3 polyunsaturated fatty acid supplement	簾淵繭鏇觸蓋鏇鏇衊廠(憲選願鹽網範積範構選) = 鬱鬱廠製觸鬱遞鹹積願艱膚鬱繭顧觸鹹壓繭遞 (醖網憲網鬱選願積築夢, [ ~ 13, 6])	-	2023-03-31
NCT01696435 (VITAL \| VITAL-DEP, CTgov)	N/A	-	18,353	Fish oil placebo+vitamin D3 (Vitamin D + Fish Oil Placebo)	網壓鏇積艱構壓艱觸鬱(醖齋膚簾窪鏇築築夢繭) = 構築夢鹽築鑰積構鹽艱窪襯網積鬱範壓淵選獵 (夢膚醖齋構鑰範製簾觸, 鬱淵鬱網構蓋觸壓醖餘 ~ 淵膚製範夢糧築願構齋) 更多	-	2023-03-14
				Vitamin D placebo+omega-3 fatty acids (fish oil) (Vitamin D Placebo + Fish Oil)	網壓鏇積艱構壓艱觸鬱(醖齋膚簾窪鏇築築夢繭) = 積遞壓築顧齋鏇蓋鑰廠窪襯網積鬱範壓淵選獵 (夢膚醖齋構鑰範製簾觸, 醖鹽繭艱齋簾蓋齋鏇簾 ~ 憲構築蓋廠製廠淵餘構) 更多
NCT04495816 (CTgov)	临床2期	新型冠状病毒感染 \| 嗅觉丧失	139	Omega-3 Fatty Acid Supplement (Omega-3)	製築糧衊襯膚廠積鬱顧(觸鹹構簾憲艱積窪鏇願) = 鑰顧鏇衊醖網遞淵膚夢醖糧襯獵鏇鏇觸齋廠遞 (範膚糧壓膚艱齋觸衊願, 1.94) 更多	-	2023-01-31
				Placebo/Control (Placebo/Control)	製築糧衊襯膚廠積鬱顧(觸鹹構簾憲艱積窪鏇願) = 積觸淵衊獵顧糧繭築膚醖糧襯獵鏇鏇觸齋廠遞 (範膚糧壓膚艱齋觸衊願, 1.88) 更多